RiverVest

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

Bonum Therapeutics is a biopharmaceutical company focused on developing innovative protein-based drugs designed to treat various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs with regulated, context-dependent activity. These drugs are engineered to sense their local environment and transition from an inactive to an active form, allowing for targeted therapeutic effects. In addition to cancer, Bonum Therapeutics also aims to address metabolic diseases, immunological conditions, and pain management, thereby expanding its potential impact across multiple therapeutic areas.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

SeQure Dx specializes in providing safety data related to CRISPR gene editing therapies, focusing on both on-target and off-target effects. The company develops genomics diagnostic technologies that facilitate target profiling for gene editing, supporting the discovery, clinical development, and diagnostic processes. Its core technologies are designed to identify potential off-target sites prior to the initiation of therapy, ensuring comprehensive confirmation of actual genetic edits. This capability empowers gene editing therapeutics developers, physicians, and patients by enhancing the safety and efficacy of gene editing treatments.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for serious liver diseases. Founded in 2018 and based in Foster City, California, the company focuses on addressing rare and orphan diseases. Its lead product candidate, maralixibat, is an investigational oral drug currently in Phase 3 clinical trials for treating progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Additionally, Mirum is developing volixibat, aimed at treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company’s commitment to innovative therapies positions it as a key player in the biopharmaceutical landscape dedicated to improving the lives of patients with debilitating liver conditions.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.

Lyric Pharmaceuticals Inc. is a clinical-stage pharmaceutical company founded in 2013 and based in South San Francisco, California. The company focuses on developing novel gastrointestinal therapeutics aimed at addressing unmet medical needs in critically ill and hospitalized patients. One of its primary products, ulimorelin, is a macrocyclic agonist of the hormone ghrelin, being developed as LP101 for the treatment of enteral feeding intolerance and other gastrointestinal disorders in the intensive care unit. Lyric's portfolio includes pro-kinetic and pro-metabolic drugs designed to improve patient care in hospital settings.

Smart Wires Technology, established in 2010, is a global provider of modular power flow control solutions for electricity transmission networks. Based in Union City, California, with offices in the U.S., U.K., and Australia, the company manufactures and distributes innovative products that optimize grid capacity, enhance reliability, and facilitate renewable energy integration. Its patented technology enables utilities to manage power flow, resolve congestion, accelerate grid projects, and minimize environmental impact.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Smart Wires Technology, established in 2010, is a global provider of modular power flow control solutions for electricity transmission networks. Based in Union City, California, with offices in the U.S., U.K., and Australia, the company manufactures and distributes innovative products that optimize grid capacity, enhance reliability, and facilitate renewable energy integration. Its patented technology enables utilities to manage power flow, resolve congestion, accelerate grid projects, and minimize environmental impact.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

IDEV Technologies is a medical device company dedicated to developing innovative products for endovascular and interventional applications, particularly in the fields of interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets SUPERA, a unique self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing. SUPERA has received approval for treating biliary strictures in the United States. Additionally, IDEV is actively enrolling patients in the SUPERB IDE trial to evaluate the stent's safety and efficacy for use in the superficial femoral artery.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Salient Surgical Technologies, Inc., established in 1999, is a privately held medical technology company that specializes in advanced energy devices for surgical procedures. Initially focusing on monopolar electrosurgical devices for liver cancer treatment, the company has since developed the AQUAMANTYS® System, which features bipolar electrosurgical technology. This system is designed to minimize surgical blood loss through its patented TRANSCOLLATION® technology, which enables the haemostatic sealing of soft tissue and bone. The AQUAMANTYS System is utilized in various surgeries, including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Salient's products are distributed in the United States, Europe, and Asia, benefiting hospitals, healthcare providers, and patients by enhancing clinical outcomes and reducing costs. To date, over 500,000 patients have undergone treatment using TRANSCOLLATION technology.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

Excaliard Pharmaceuticals is a biotechnology company that specializes in the development and commercialization of antisense drugs aimed at treating scarring and other fibrotic diseases. The firm focuses on creating targeted therapeutics that address dermatological disorders, providing innovative solutions for patients suffering from various skin conditions. By employing advanced antisense technology, Excaliard aims to improve treatment outcomes for individuals with fibrotic diseases, enhancing their quality of life through effective localized therapies.

Xoft, Inc. specializes in developing electronic brachytherapy (eBx) systems for radiation oncology applications. The company offers a range of products, including the Axxent Controller, which employs a miniaturized high dose rate X-ray source to deliver radiation directly to cancerous tumor beds. Other products include the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, Xoft provides various accessories such as physics accessory kits, personnel protective shields, and patient care kits, along with FlexiShield, designed to minimize radiation exposure to healthy tissues and organs. The company's products are primarily utilized in the treatment of early stage breast cancer, skin cancer, and endometrial cancer. Xoft distributes its offerings through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, the company was previously known as Xoft microTube, Inc. before rebranding in 2004.

Calypso Medical Technologies, based in Seattle, is a privately held medical device company specializing in tumor localization technology. The company's proprietary system employs miniaturized implanted devices known as Beacon electromagnetic transponders to continuously and accurately track the location of tumors, enhancing the precision and management of radiation therapy delivery. This technology is particularly aimed at body-wide cancers that are commonly treated with radiation. Calypso's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, ensuring compliance with regulatory standards. The company has established strategic partnerships with leading organizations in the medical field, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical, to further its mission of improving cancer treatment outcomes.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Centerre Healthcare Corporation, founded in 2002 and based in Brentwood, Tennessee, operates rehabilitation hospitals that focus on comprehensive care for patients recovering from various conditions. The organization offers specialized inpatient rehabilitation services for individuals dealing with strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and orthopedic issues such as hip and knee replacements. Centerre Healthcare is dedicated to addressing the medical, psychological, social, and functional needs of its patients, aiming to support their independence and enhance their quality of life following injury or illness.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.

Salient Surgical Technologies, Inc., established in 1999, is a privately held medical technology company that specializes in advanced energy devices for surgical procedures. Initially focusing on monopolar electrosurgical devices for liver cancer treatment, the company has since developed the AQUAMANTYS® System, which features bipolar electrosurgical technology. This system is designed to minimize surgical blood loss through its patented TRANSCOLLATION® technology, which enables the haemostatic sealing of soft tissue and bone. The AQUAMANTYS System is utilized in various surgeries, including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Salient's products are distributed in the United States, Europe, and Asia, benefiting hospitals, healthcare providers, and patients by enhancing clinical outcomes and reducing costs. To date, over 500,000 patients have undergone treatment using TRANSCOLLATION technology.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

NexRay is a provider of medical x-ray fluoroscopy systems.

Salient Surgical Technologies, Inc., established in 1999, is a privately held medical technology company that specializes in advanced energy devices for surgical procedures. Initially focusing on monopolar electrosurgical devices for liver cancer treatment, the company has since developed the AQUAMANTYS® System, which features bipolar electrosurgical technology. This system is designed to minimize surgical blood loss through its patented TRANSCOLLATION® technology, which enables the haemostatic sealing of soft tissue and bone. The AQUAMANTYS System is utilized in various surgeries, including orthopaedic reconstruction, spine surgery, orthopaedic trauma, and surgical oncology. Salient's products are distributed in the United States, Europe, and Asia, benefiting hospitals, healthcare providers, and patients by enhancing clinical outcomes and reducing costs. To date, over 500,000 patients have undergone treatment using TRANSCOLLATION technology.